Day One Biopharmaceuticals/$DAWN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Day One Biopharmaceuticals
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
Ticker
$DAWN
Sector
Primary listing
Employees
178
Headquarters
Website
DAWN Metrics
BasicAdvanced
$2.2B
-
-$1.04
-1.27
-
Price and volume
Market cap
$2.2B
Beta
-1.27
52-week high
$21.40
52-week low
$5.64
Average daily volume
5.2M
Financial strength
Current ratio
8.015
Quick ratio
7.73
Long term debt to equity
0.594
Total debt to equity
0.633
Profitability
EBITDA (TTM)
-124.274
Gross margin (TTM)
89.12%
Net profit margin (TTM)
-67.85%
Operating margin (TTM)
-80.76%
Effective tax rate (TTM)
1.81%
Revenue per employee (TTM)
$890,000
Management effectiveness
Return on assets (TTM)
-14.64%
Return on equity (TTM)
-22.74%
Valuation
Price to revenue (TTM)
13.917
Price to book
4.98
Price to tangible book (TTM)
5.19
Price to free cash flow (TTM)
-20.463
Free cash flow yield (TTM)
-4.89%
Free cash flow per share (TTM)
-1.042
Growth
Revenue change (TTM)
20.60%
Earnings per share change (TTM)
1.54%
3-year earnings per share growth (CAGR)
-21.76%
What the Analysts think about DAWN
Analyst ratings (Buy, Hold, Sell) for Day One Biopharmaceuticals stock.
DAWN Financial Performance
Revenues and expenses
DAWN Earnings Performance
Company profitability
DAWN News
AllArticlesVideos
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN
Business Wire·4 days ago
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN)
Newsfile Corp·4 days ago
Day One Shares Surge After $2.5B Servier Deal
Benzinga·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Day One Biopharmaceuticals stock?
Day One Biopharmaceuticals (DAWN) has a market cap of $2.2B as of March 10, 2026.
What is the P/E ratio for Day One Biopharmaceuticals stock?
The price to earnings (P/E) ratio for Day One Biopharmaceuticals (DAWN) stock is 0 as of March 10, 2026.
Does Day One Biopharmaceuticals stock pay dividends?
No, Day One Biopharmaceuticals (DAWN) stock does not pay dividends to its shareholders as of March 10, 2026.
When is the next Day One Biopharmaceuticals dividend payment date?
Day One Biopharmaceuticals (DAWN) stock does not pay dividends to its shareholders.
What is the beta indicator for Day One Biopharmaceuticals?
Day One Biopharmaceuticals (DAWN) has a beta rating of -1.27. This means that it has an inverse relation to market volatility.